Lenacapavir Study

STUDY BASICS

Are you an HIV-negative woman who has never used PrEP (Pre-Exposure Prophylaxis)? Are you 18-50 years old? You may be able to participate in a study of an experimental drug named Lenacapavir (LEN) being developed to prevent human immunodeficiency virus (HIV) infection. This study involves at least 27 visits over about 2 years. Compensation is provided.

RESEARCH AREAS:

Healthy Volunteer

AGE: 18-50

SEX ASSIGNED AT BIRTH: Female

DURATION: About 2 years
VISITS: At least 27

LOCATION: UPMC Magee-Womens Hospital Clinical Translational Research Center (MWH CTRC) - Oakland

COMPENSATION: Participants may receive a total of $2980

Contact:

Sherri Karas Certo

Sjk91@pitt.edu

412-383-1313